The purpose of this guidance is to identify the types of decision support software functionalities that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the definition of a device but for which FDA does not intend to enforce compliance with applicable requirements of the FD&C Act, including, but not limited to, premarket clearance and premarket approval requirements; and (3) FDA intends to focus its regulatory oversight on.
News & Trends
Procurar
Recentes
- MDCG 2021-5 Rev. 1 .Guidance on standardisation for medical devices
- Qualification of novel methodologies (QoNM) for medicinal product development . Procedural Guidance to applicants
- FDA Guidance for Drug Development
- Study supporting the monitoring of the availability of medical devices on the EU market. 2 July 2026
- IMDRF Technical Framework for Artificial Intelligence Life Cycle Management” (IMDRF AIML WG N93 – April 2026)
- GMP CANÁBIS 2026 : “Formação conduzida com profundo domínio teórico e prático “
- MHRA Open consultation Draft rare disease therapies regulatory framework
- EU Delegated Acts on Well-Established Technologies (WET) under the MDR